Thermo Fisher Scientific (TMO) Projected to Post Earnings on Thursday

Thermo Fisher Scientific (NYSE:TMO) will likely be posting its quarterly earnings results before the market opens on Thursday, January 30th. Analysts expect Thermo Fisher Scientific to post earnings of $5.94 per share and revenue of $11,293,741.66 billion for the quarter. Parties interested in listening to the company’s conference call can do so using this link.

Thermo Fisher Scientific Trading Up 1.5 %

Thermo Fisher Scientific stock opened at $583.43 on Tuesday. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.26 and a current ratio of 1.63. The stock has a market cap of $223.16 billion, a PE ratio of 36.58, a price-to-earnings-growth ratio of 3.82 and a beta of 0.76. The stock has a 50-day moving average of $533.60 and a two-hundred day moving average of $569.81. Thermo Fisher Scientific has a one year low of $493.30 and a one year high of $627.88.

Thermo Fisher Scientific declared that its board has initiated a share buyback program on Friday, November 15th that authorizes the company to repurchase $4.00 billion in shares. This repurchase authorization authorizes the medical research company to buy up to 2% of its shares through open market purchases. Shares repurchase programs are usually an indication that the company’s management believes its stock is undervalued.

Thermo Fisher Scientific Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, January 15th. Investors of record on Friday, December 13th were given a $0.39 dividend. This represents a $1.56 annualized dividend and a dividend yield of 0.27%. The ex-dividend date of this dividend was Friday, December 13th. Thermo Fisher Scientific’s payout ratio is currently 9.78%.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 5,850 shares of the firm’s stock in a transaction on Friday, November 1st. The stock was sold at an average price of $557.89, for a total value of $3,263,656.50. Following the transaction, the chief executive officer now owns 121,192 shares in the company, valued at approximately $67,611,804.88. This trade represents a 4.60 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In the last three months, insiders have sold 34,850 shares of company stock valued at $19,123,197. 0.34% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several research firms recently issued reports on TMO. TD Cowen upped their target price on Thermo Fisher Scientific from $656.00 to $686.00 in a research report on Tuesday, October 22nd. Bernstein Bank raised their price objective on Thermo Fisher Scientific from $565.00 to $625.00 and gave the stock a “market perform” rating in a research note on Tuesday, October 22nd. Stifel Nicolaus dropped their target price on Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating on the stock in a research report on Thursday, October 24th. Sanford C. Bernstein raised shares of Thermo Fisher Scientific from a “market perform” rating to an “outperform” rating and set a $630.00 price target for the company in a research report on Friday, January 10th. Finally, StockNews.com upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Tuesday, January 14th. Four investment analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $648.95.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.